40 related articles for article (PubMed ID: 17276944)
1. Could the mitotic count improve personalized prognosis in melanoma patients?
Buja A; Rugge M; Cozzolino C; Dossi F; Zorzi M; Vecchiato A; de Luca G; Del Fiore P; Tropea S; dall'Olmo L; Rossi CR; Boccuzzo G; Mocellin S
PLoS One; 2024; 19(4):e0302309. PubMed ID: 38626072
[TBL] [Abstract][Full Text] [Related]
2. Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study.
Litzner BR; Etufugh CN; Stepenaskie S; Hynan LS; Cockerell CJ
Am J Dermatopathol; 2012 Dec; 34(8):827-32. PubMed ID: 22878366
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Cyclooxygenase-2 Expression in Association with Clinical-Pathological Factors in Malignant Melanoma.
Jafarian AH; Mohamadian Roshan N; Gharib M; Moshirahmadi V; Tasbandi A; Ayatollahi AA; Ayatollahi H
Iran J Pathol; 2019; 14(2):96-103. PubMed ID: 31528165
[TBL] [Abstract][Full Text] [Related]
4. Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.
Lasota J; Kowalik A; Felisiak-Golabek A; Zięba S; Waloszczyk P; Masiuk M; Wejman J; Szumilo J; Miettinen M
Mod Pathol; 2019 Jul; 32(7):957-966. PubMed ID: 30760858
[TBL] [Abstract][Full Text] [Related]
5. Dormancy of growth-stunted malignant melanoma: sustainable and smoldering patterns.
Piérard-Franchimont C; Hermanns-Lê T; Delvenne P; Piérard GE
Oncol Rev; 2014 Sep; 8(2):252. PubMed ID: 25992239
[TBL] [Abstract][Full Text] [Related]
6. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
[TBL] [Abstract][Full Text] [Related]
7. Thigmotropism of malignant melanoma cells.
Quatresooz P; Piérard-Franchimont C; Noël F; Piérard GE
Dermatol Res Pract; 2012; 2012():362784. PubMed ID: 22203839
[TBL] [Abstract][Full Text] [Related]
8. Smouldering malignant melanoma and metastatic dormancy: an update and review.
Piérard GE; Piérard-Franchimont C; Reginster MA; Quatresooz P
Dermatol Res Pract; 2012; 2012():461278. PubMed ID: 22110487
[TBL] [Abstract][Full Text] [Related]
9. Malignant melanoma in the elderly: different regional disease and poorer prognosis.
Macdonald JB; Dueck AC; Gray RJ; Wasif N; Swanson DL; Sekulic A; Pockaj BA
J Cancer; 2011; 2():538-43. PubMed ID: 22084644
[TBL] [Abstract][Full Text] [Related]
10. [Mitosis in early invasive malignant melanoma. How reliable is histogenetic classification at stage pT1?].
Bösmüller H; Haitchi-Petnehazy S; Hintringer T; Mentzel T
Pathologe; 2012 Mar; 33(2):113-7. PubMed ID: 21845361
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.
Thompson JF; Soong SJ; Balch CM; Gershenwald JE; Ding S; Coit DG; Flaherty KT; Gimotty PA; Johnson T; Johnson MM; Leong SP; Ross MI; Byrd DR; Cascinelli N; Cochran AJ; Eggermont AM; McMasters KM; Mihm MC; Morton DL; Sondak VK
J Clin Oncol; 2011 Jun; 29(16):2199-205. PubMed ID: 21519009
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and treatment of melanoma in elderly patients.
Tsai S; Balch C; Lange J
Nat Rev Clin Oncol; 2010 Mar; 7(3):148-52. PubMed ID: 20142815
[TBL] [Abstract][Full Text] [Related]
14. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.
Bogunovic D; O'Neill DW; Belitskaya-Levy I; Vacic V; Yu YL; Adams S; Darvishian F; Berman R; Shapiro R; Pavlick AC; Lonardi S; Zavadil J; Osman I; Bhardwaj N
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20429-34. PubMed ID: 19915147
[TBL] [Abstract][Full Text] [Related]
15. Surgery and radiotherapy in the treatment of cutaneous melanoma.
Testori A; Rutkowski P; Marsden J; Bastholt L; Chiarion-Sileni V; Hauschild A; Eggermont AM
Ann Oncol; 2009 Aug; 20 Suppl 6(Suppl 6):vi22-9. PubMed ID: 19617294
[TBL] [Abstract][Full Text] [Related]
16. Mitotic rate in melanoma: a reexamination.
Attis MG; Vollmer RT
Am J Clin Pathol; 2007 Mar; 127(3):380-4. PubMed ID: 17276944
[TBL] [Abstract][Full Text] [Related]
17. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
[TBL] [Abstract][Full Text] [Related]
18. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.
Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y
Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514
[TBL] [Abstract][Full Text] [Related]
19. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
